Abstract
AIMS To study the relationship between the toxicity associated with a 5-FU-based therapy and the presence of (i) the large intragenic rearrangements in the DPYD gene and (ii) the IVS14+1G>A mutation. METHODS We used the multiplex ligation-dependent probe amplification technique (MLPA) to study genomic DNA from 234 colorectal cancer patients treated with 5-FU-based chemotherapy. RESULTS We did not detect any deletion/duplication in the DPYD gene. The presence of the IVS14+1G>A mutation was also excluded. CONCLUSIONS Neither the large genomic rearrangements in the DPYD gene nor the IVS14+1G>A mutation play a significant role in the development of serious toxicity associated with a 5-FU containing regimen. © 2010 The British Pharmacological Society.
Original language | English |
---|---|
Pages (from-to) | 268-272 |
Journal | British Journal of Clinical Pharmacology |
Volume | 70 |
Issue number | 2 |
DOIs | |
Publication status | Published - 1 Aug 2010 |
Keywords
- 5-FU
- Dihydropyrimidine dehydrogenase gene
- Multiplex ligation-dependent probe amplification (MLPA)